ADX-10061

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529411

CAS#: 128022-68-4

Description: ADX-10061, also known as CEE-03-310 and NNC-01-0687, is a dopamine D1 receptor antagonist potentially for the treatment of smoking cessation, sleep disorder

Chemical Structure

img
ADX-10061
CAS# 128022-68-4
Instruction

Theoretical Analysis

MedKoo Cat#: 529411
Name: ADX-10061
CAS#: 128022-68-4
Chemical Formula: C19H20N2O4
Exact Mass: 340.14
Molecular Weight: 340.379
Elemental Analysis: C, 67.05; H, 5.92; N, 8.23; O, 18.80

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ADX-10061; CEE-310; CEE-03-310; NNC-01-0687; NNC-687; ADX10061; CEE310; CEE03310; NNC010687; NNC687; ADX 10061; CEE 310; CEE 03 310; NNC 01 0687; NNC 687

IUPAC/Chemical Name: (S)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol

InChi Key: XZPSYCOYKJRHKE-MRXNPFEDSA-N

InChi Code: InChI=1S/C19H20N2O4/c1-20-7-5-13-9-17(21(23)24)18(22)10-15(13)16(11-20)14-4-2-3-12-6-8-25-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1

SMILES Code: OC1=C([N+]([O-])=O)C=C2CCN(C)C[C@H](C3=C(OCC4)C4=CC=C3)C2=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 340.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Grodum E, Andersen M, Hangaard J, Koldkjaer O, Hagen C. Lack of effect of the dopamine D1 antagonist, NNC 01-0687, on unstimulated and stimulated release of anterior pituitary hormones in males. J Endocrinol Invest. 1998 May;21(5):291-7. PubMed PMID: 9648050.

2: Skrumsager BK, Christensen JV, Snel S, Seiberling M. Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. Psychopharmacology (Berl). 1995 Oct;121(3):294-9. PubMed PMID: 8584609.

3: Karle J, Clemmesen L, Hansen L, Andersen M, Andersen J, Fensbo C, Sloth-Nielsen M, Skrumsager BK, Lublin H, Gerlach J. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (Berl). 1995 Oct;121(3):328-9. PubMed PMID: 8584614.

4: Christensen JV. Determination of (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5- tetrahydro-1H-3-benzazepin-7-ol (NNC 01-0687), a novel dopamine D-1 receptor antagonist, in plasma by solid-phase extraction and high-performance liquid chromatography. J Chromatogr. 1992 Jun 10;577(2):366-70. PubMed PMID: 1301070.

5: Eder DN, Zdravkovic M, Wildschiødtz G. Selective alterations of the first NREM sleep cycle in humans by a dopamine D1 receptor antagonist (NNC-687). J Psychiatr Res. 2003 Jul-Aug;37(4):305-12. PubMed PMID: 12765853.

6: Eder DN. CEE-03-310 CeNeS pharmaceuticals. Curr Opin Investig Drugs. 2002 Feb;3(2):284-8. Review. PubMed PMID: 12020061.

7: Ahlenius S. Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol. 1999 May;84(5):193-6. Review. PubMed PMID: 10361974.

8: Salmi P, Ahlenius S. Dihydrexidine produces hypothermia in rats via activation of dopamine D1 receptors. Neurosci Lett. 1997 Oct 24;236(1):57-9. PubMed PMID: 9404951.

9: Salmi P, Ahlenius S. Further evidence for clozapine as a dopamine D1 receptor agonist. Eur J Pharmacol. 1996 Jun 20;307(1):27-31. PubMed PMID: 8831100.

10: Halldin C, Foged C, Farde L, Karlsson P, Hansen K, Grønvald F, Swahn CG, Hall H, Sedvall G. [11C]NNC 687 and [11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. Nucl Med Biol. 1993 Nov;20(8):945-53. PubMed PMID: 8298574.

11: Karlsson P, Farde L, Halldin C, Swahn CG, Sedvall G, Foged C, Hansen KT, Skrumsager B. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl). 1993;113(2):149-56. PubMed PMID: 7855175.

12: Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):45-52. PubMed PMID: 1397049.

13: Nielsen EB, Andersen PH. Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):35-44. PubMed PMID: 1397048.